UPDATE: AxoGen (AXGN) Reports In-Line Q1 EPS

(Updated - April 30, 2018 5:43 PM EDT)

(Updates shows adjusted EPS)

AxoGen (NASDAQ: AXGN) reported Q1 EPS of ($0.11), in-line with the analyst estimate of ($0.11). Revenue for the quarter came in at $17.3 million versus the consensus estimate of $17.08 million.

Management reiterates 2018 revenue will grow at least 40% over 2017 revenue and gross margins will remain above 80%. Additionally, management now expects to have at least 80 direct sales reps by year end, compared to the previous estimate of at least 75.

For earnings history and earnings-related data on AxoGen (AXGN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Mohawk Industries (MHK) Tops Q1 EPS by 19c
• Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance